MA30478B1 - Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia. - Google Patents

Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia.

Info

Publication number
MA30478B1
MA30478B1 MA31406A MA31406A MA30478B1 MA 30478 B1 MA30478 B1 MA 30478B1 MA 31406 A MA31406 A MA 31406A MA 31406 A MA31406 A MA 31406A MA 30478 B1 MA30478 B1 MA 30478B1
Authority
MA
Morocco
Prior art keywords
aliphatic alcohol
composition
griffonia simplicifolia
high aliphatic
source
Prior art date
Application number
MA31406A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA30478B1 publication Critical patent/MA30478B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La présente invention concerne de nouvelles compositions comprenant une combinaison d'au moins un alcool aliphatique primaire supérieur de préférence choisi parmi ceux ayant de 18 à 40 atomes de carbone ou des mélanges de ceux-ci, d'au moins une source de 5-hydroxytryptophane (5-HTP) comprenant éventuellement en plus une source de caféine et/ou de catéchine-polyphénol et/ou de gallate d'épigallocatéchine en tant qu'agents actifs, seule ou en combinaison avec un ou plusieurs autres agents actifs, éventuellement avec un ou plusieurs excipients. En particulier, l'invention concerne des compositions et leur procédé de préparation et leur procédé d'utilisation pour lutter contre l'obésité et les troubles associés.
MA31406A 2006-05-11 2008-11-24 Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia. MA30478B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1175DE2006 2006-05-11

Publications (1)

Publication Number Publication Date
MA30478B1 true MA30478B1 (fr) 2009-06-01

Family

ID=38693600

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31406A MA30478B1 (fr) 2006-05-11 2008-11-24 Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia.

Country Status (15)

Country Link
US (1) US7956067B2 (fr)
EP (1) EP2029152A4 (fr)
JP (1) JP2009536640A (fr)
KR (1) KR20090017591A (fr)
CN (1) CN101443026A (fr)
AU (1) AU2007251121A1 (fr)
BR (1) BRPI0711631A2 (fr)
CA (1) CA2651639A1 (fr)
CR (1) CR10495A (fr)
EA (1) EA200870526A1 (fr)
MA (1) MA30478B1 (fr)
MX (1) MX2008014407A (fr)
RS (1) RS20080536A (fr)
TN (1) TNSN08451A1 (fr)
WO (1) WO2007132479A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITTO20070391A1 (it) * 2007-06-05 2008-12-06 Medestea Res & Production S P Composizione di integratore alimentare,farmaco o dispositivo medicale e suo impiego per sopprimere l'appetito, migliorare tono ed umore, con attivita antidepressiva naturale e con effetto antiastenico
EP2016946B1 (fr) * 2007-07-18 2013-02-27 The Jordanian Pharmaceutical Manufacturing Co. Composition de coprécipité de chitosane et de dioxyde de silicium pour une utilisation en tant qu'agent thérapeutique
US8455024B2 (en) 2008-10-16 2013-06-04 Visalus Holdings, Llc Appetite suppressant composition
JP2010150207A (ja) * 2008-12-26 2010-07-08 Noevir Co Ltd 保湿剤、抗老化剤、抗酸化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤
ES2386858B1 (es) * 2011-02-07 2013-03-22 Eduardo Antonio Gómez De Diego Composición adelgazante natural.
KR101492213B1 (ko) * 2012-10-30 2015-02-16 한국식품연구원 폴리코사놀을 유효성분으로 하는 히스타민 수용체 길항제 조성물
CN103265472A (zh) * 2013-05-16 2013-08-28 成都都江堰市芳华园林有限责任公司 加纳籽提取物结晶母液分离5-羟基色氨酸的方法
AU2014306366B9 (en) 2013-08-16 2020-03-26 Poly Gain Pte Ltd Sugar cane derived extracts and methods of treatment
US9226950B2 (en) * 2013-11-12 2016-01-05 National Dong Hwa University Method and composition for treating diabetes mellitus
IT201600129412A1 (it) * 2016-12-21 2018-06-21 Fb Health S P A Composizione per prevenire o trattare discinesie
CN109363029A (zh) * 2018-11-01 2019-02-22 昆明学院 一种竹叶口味苏打水及其制备方法
CN110101689A (zh) * 2019-05-24 2019-08-09 江西省科学院生物资源研究所 二十八烷醇在制备预防肝损伤药物中的应用
GB202017255D0 (en) * 2020-10-30 2020-12-16 Queens Univ Of Belfast Immunomodulatory agent
IT202100005429A1 (it) * 2021-03-09 2022-09-09 Ngn Healthcare New Generation Nutraceuticals S R L Integratore alimentare per favorire la perdita di peso corporeo
IT202300027672A1 (it) * 2023-12-21 2025-06-21 Cor Con Int Srl Integratore per l'uso nel trattamento delle comorbidita' associate a terapia farmacologica antiepilettica

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610277B2 (en) * 2000-12-27 2003-08-26 Arthur Zuckerman Appetite suppressant toothpaste
US20030162725A1 (en) * 2002-02-25 2003-08-28 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity with EGCG
US20040071681A1 (en) * 2002-10-10 2004-04-15 Lydia Muller Method and composition for reducing cravings for a craved substance
US7034060B2 (en) * 2003-01-31 2006-04-25 Unigen Pharmaceuticals, Inc. Polycosanols from Ericerus pela wax
CN1569093A (zh) * 2003-07-21 2005-01-26 蒋佃水 生物醒脑抗疲劳剂

Also Published As

Publication number Publication date
CR10495A (es) 2009-01-27
WO2007132479A1 (fr) 2007-11-22
KR20090017591A (ko) 2009-02-18
US7956067B2 (en) 2011-06-07
MX2008014407A (es) 2008-11-27
AU2007251121A1 (en) 2007-11-22
CA2651639A1 (fr) 2007-11-22
TNSN08451A1 (en) 2010-04-14
JP2009536640A (ja) 2009-10-15
EA200870526A1 (ru) 2009-04-28
US20090258896A1 (en) 2009-10-15
CN101443026A (zh) 2009-05-27
BRPI0711631A2 (pt) 2011-12-06
EP2029152A4 (fr) 2011-03-02
EP2029152A1 (fr) 2009-03-04
RS20080536A (sr) 2009-05-06

Similar Documents

Publication Publication Date Title
MA30478B1 (fr) Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia.
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MA33726B1 (fr) Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
WO2009091576A3 (fr) Préparations parentérales d'agonistes de dopamine
MX2007004783A (es) Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
MA30487B1 (fr) Nouveaux composes heterocycliques
MY143795A (en) Tetrahydropyridoindole derivatives
MY160256A (en) Novel indole compounds
WO2006067614A3 (fr) Derives heteroaromatiques utiles en tant qu'agents anticancereux
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
Fitzgerald et al. Monoamine oxidase‐A knockdown in human neuroblastoma cells reveals protection against mitochondrial toxins
TW200740799A (en) Alpha2C adrenoreceptor agonists
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
MA30296B1 (fr) Nouvelles amines
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
MY140410A (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
MA30292B1 (fr) Amines primaires comme inhibiteurs de la renine
GB0524814D0 (en) Compounds